The 4th workshop of the UICC project on screening for cancer was held in Helsinki, Finland on April 7-9, 1986. In developed countries there are more data available from controlled trials on the effectiveness of screening for breast cancer than for any other cancer. Nevertheless, full information is
A model-based analysis of the hip project for breast cancer screening
β Scribed by G. J. Van Oortmarssen; J. D. F. Habbema; J. T. H. N. Lubbe; P. J. Van Der Maas
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- French
- Weight
- 763 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
A computer simulation approach is used to test assumptions about sensitivity of mammography and physical examination, and about the duration of preclinical screendetectable breast cancer. Values between 50% and 80% for the combined sensitivity of the 2 tests give a good explanation of the results of the HIP randomized trial of breast cancer screening. The mean duration of the preclinical stage can vary from 1.6 years for high sensitivity values to 2.7 years for low values. In comparison with previous analyses of the HIP data, our estimate for the sensitivity is lower, and the mean duration of the preclinical stage is longer. This is a consequence of the use of a more detailed model in our analysis, allowing for a more complete use of the HIP data in testing model assumptions. Similar analyses of data from recent screening projects in The Netherlands resulted in compatible estimates for the duration of preclinical breast cancer.
π SIMILAR VOLUMES
## BACKGROUND. Although the efficacy of mass screening for colorectal carcinoma (CRC) with a fecal occult blood test has been demonstrated in several randomized trials, a mass screening approach used in countries with intermediate or low incidence of CRC might be costly. Screening high risk people
## Abstract ## BACKGROUND. No benchmarks exist in the screened breast cancer population to establish the optimal proportions of newly detected cancer patients who should receive the ideal treatment. The aim of the study was to estimate the optimal proportion of cases diagnosed in a breastβscreenin